A retrospective analysis comparing stage III ALK-positive NSCLC patients undergoing radical resection after neoadjuvant therapy with either alectinib (16 patients) or crizotinib (13 patients) demonstrated higher pathological complete response rates in the alectinib group (37.5% vs. 15.4%) [62]. This evidence concerns the gene ALK and non-small cell lung carcinoma.